NCT02371746View on ClinicalTrials.gov

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

February 13, 2019

Study Completion Date

February 13, 2019

Conditions
Glaucoma and Ocular Hypertension
Interventions
DRUG

ENV515-3 Travoprost XR

DRUG

ENV515-1 Travoprost XR

DRUG

ENV515-3-2 Travoprost XR

Trial Locations (14)

30260

Morrow

45242

Cincinnati

46260

Indianapolis

57108

Sioux Falls

63017

Chesterfield

64133

Kansas City

77025

Houston

78229

San Antonio

78731

Austin

85225

Chandler

90301

Inglewood

92843

Garden Grove

96002

Redding

97210

Portland

Sponsors
All Listed Sponsors
lead

Envisia Therapeutics

INDUSTRY